Last checked at 12 May 2016 09:30
("Deltex Medical" or the "Company")
Directors' Shareholdings/Issue of equity
Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), announces that it has issued a total of 1,850,522 new ordinary shares of 1p each in the Company ("New Ordinary Shares") at a price of 4.00 pence per share.
The four non-executive directors named below have elected to take 1,850,522 New Ordinary Shares in lieu of a cash payment as remuneration for their services to the Company for the period 1 April 2015 to 31 March 2016.
Accordingly, application has been made for these New Ordinary Shares to be admitted to trading on AIM. The shares rank pari passu with the existing issued shares of the Company. Admission to trading on AIM and dealings in the New Ordinary Shares are expected to commence on 18 May 2016. Following the issue of these new shares the Company will have a total of 274,470,066 ordinary shares of 1p each in issue.
Following this issue, the relevant Directors' beneficial interests are as follows:
Name of Director | Number of New Ordinary Shares issued in lieu of fees/salary
| Holding of shares following issue of New Ordinary Shares
| % of enlarged issued share capital |
Nigel Keen | 833,325 | 22,055,849 | 8.04 |
Sir Duncan Nichol | 330,000 | 1,586,912 | 0.58 |
Julian Cazalet | 330,000 | 6,456,123 | 2.35 |
Mark Wippell | 357,197 | 1,108,444 | 0.40 |
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 investorinfo@deltexmedical.com |
Nigel Keen, Chairman | |
Ewan Phillips, Chief Executive | |
Jonathan Shaw, Group Finance Director Barry Curtis, Company Secretary | |
Nominated Adviser & Broker | |
Arden Partners plc | 020 7614 5900 |
Chris Hardie | |
Joint Broker Zeus Capital Limited Phil Walker Dominic Wilson
|
020 3829 5000
|
Financial Public Relations | |
IFC Advisory | 0203 053 8671 |
Tim Metcalfe Graham Herring Heather Armstrong |
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
Company goal
ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.
The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the world and over 650,000 patients have been treated to date using Deltex Medical's single patient disposable probes.